In designing the study questions, the EPC consulted several Key Informants who represent the end-users of research. The EPC sought the Key Informant input on the priority areas for research and synthesis. Key Informants are not involved in the analysis of the evidence or the writing of the report. Therefore, in the end, study questions, design, methodological approaches, and/or conclusions do not necessarily represent the views of individual Key Informants.

Key Informants must disclose any financial conflicts of interest greater than $10,000 and any other relevant business or professional conflicts of interest. Because of their role as end-users, individuals with potential conflicts may be retained. The TOO and the EPC work to balance, manage, or mitigate any conflicts of interest.

Three Key Informants could not be contacted to obtain permission for listing them here. The list of the other Key Informants who participated in developing this report follows:

• Gordon Huggins, M.D.
  Associate Professor of Medicine
  Tufts University
  Faculty, Institute for Clinical Research and Health Policy
  Tufts Medical Center
  Boston, MA
• David Kent, M.D., C.M., M.Sc.
  Associate Professor of Medicine and Neurology, Tufts Medical Center and Tufts University School of Medicine
  Associate Professor of Clinical and Translational Science
  Director, Clinical and Translational Science Program, Sackler School of Graduate Biomedical Sciences, Tufts University
  Boston, MA
• Mary Ross Southworth, Pharm.D.
  Deputy Director for Safety, Office of New Drugs
  Division of Cardiovascular and Renal Products
  U.S. Food and Drug Administration
  Silver Spring, MD